Biora Therapeutics(BIOR)
搜索文档
Progenity (PROG) Investor Presentation - Slideshow
2020-12-03 00:07
Preeclampsia R&D Day Mathew Cooper, PhD, MBA Chief Scientific Officer November 20, 2020 | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...
Biora Therapeutics(BIOR) - 2020 Q3 - Earnings Call Presentation
2020-11-11 02:27
progenity® 1 ©2020 Progenity, Inc. All rights reserved. 1 Business Update and Third Quarter 2020 Financial Results November 9, 2020 2 ©2020 Progenity, Inc. All rights reserved. 2 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this presentation ...
Biora Therapeutics(BIOR) - 2020 Q3 - Earnings Call Transcript
2020-11-10 11:30
Progenity, Inc. (PROG) Q3 2020 Earnings Conference Call November 9, 2020 4:30 PM ET Company Participants Robert Uhl - Managing Director-Westwicke ICR Harry Stylli - Chairman and Chief Executive Officer Eric d’Esparbes - Chief Financial Officer Conference Call Participants Steven Mah - Piper Sandler Catherine Schulte - Baird Andrew Cooper - Raymond James Dan Leonard - Wells Fargo Operator Welcome to the Progenity Third Quarter 2020 Earnings Call. At this time, all participants are in a listen-only mode. La ...
Biora Therapeutics(BIOR) - 2020 Q3 - Quarterly Report
2020-11-10 05:38
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share PROG The Nasdaq Global Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...
Biora Therapeutics(BIOR) - 2020 Q2 - Quarterly Report
2020-08-15 04:08
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share PROG The Nasdaq Global Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File ...
Biora Therapeutics(BIOR) - 2020 Q2 - Earnings Call Transcript
2020-08-14 09:30
Progenity, Inc. (PROG) Q2 2020 Earnings Conference Call August 13, 2020 4:30 PM ET Company Participants Robert Uhl – Managing Director-Westwicke ICR Harry Stylli – Chairman and Chief Executive Officer Eric d’Esparbes – Chief Financial Officer Conference Call Participants Steven Mah – Piper Sandler Lisa Phan – Wells Fargo Catherine Schulte – Baird Andrew Cooper – Raymond James Operator Welcome to the Progenity’s Second Quarter 2020 Earnings Call. At this time, all participant lines are in a listen-only mode. ...